Until now, only experimental compounds (for example, drugs inhibiting PARP57, 58, 59, ATR60) have displayed a preferential toxicity in ATM loss-of-function cancer cells and none have been validated in lung tumours, where ATM is frequently mutated2, 4, 5. This evidence concerns the gene ATM and cancer.